Oppenheimer Holdings Inc. Reaffirms “Buy” Rating for Integra Lifesciences Holdings Corp (IART)

Oppenheimer Holdings Inc. restated their buy rating on shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) in a research report report published on Wednesday.

A number of other equities research analysts have also weighed in on IART. Zacks Investment Research upgraded shares of Integra Lifesciences Holdings Corp from a hold rating to a buy rating and set a $48.00 price objective for the company in a report on Thursday, January 5th. Barclays PLC restated an equal weight rating and issued a $42.00 price objective (down from $84.00) on shares of Integra Lifesciences Holdings Corp in a report on Friday, January 13th. Royal Bank of Canada restated a hold rating and issued a $85.00 price objective on shares of Integra Lifesciences Holdings Corp in a report on Friday, January 6th. JMP Securities upgraded shares of Integra Lifesciences Holdings Corp from a market perform rating to an outperform rating and set a $50.00 price objective for the company in a report on Friday, January 6th. Finally, Piper Jaffray Companies restated an overweight rating and issued a $47.00 price objective on shares of Integra Lifesciences Holdings Corp in a report on Wednesday, March 22nd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $47.28.

Analyst Recommendations for Integra Lifesciences Holdings Corp (NASDAQ:IART)

Integra Lifesciences Holdings Corp (NASDAQ:IART) opened at 43.00 on Wednesday. The company’s 50-day moving average is $42.95 and its 200 day moving average is $65.93. Integra Lifesciences Holdings Corp has a 52 week low of $32.01 and a 52 week high of $45.87. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of 45.74 and a beta of 0.80.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last announced its earnings results on Thursday, February 23rd. The company reported $0.52 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.52. Integra Lifesciences Holdings Corp had a net margin of 6.09% and a return on equity of 16.11%. The business earned $255.70 million during the quarter, compared to analyst estimates of $257.27 million. During the same period in the previous year, the business posted $0.44 earnings per share. Integra Lifesciences Holdings Corp’s revenue for the quarter was up 6.0% on a year-over-year basis. On average, analysts forecast that Integra Lifesciences Holdings Corp will post $1.91 EPS for the current fiscal year.

WARNING: This story was first posted by Mideast Time and is the sole property of of Mideast Time. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.mideasttime.com/oppenheimer-holdings-inc-reaffirms-buy-rating-for-integra-lifesciences-holdings-corp-iart/1589788.html.

Several large investors have recently made changes to their positions in the company. LS Investment Advisors LLC raised its stake in shares of Integra Lifesciences Holdings Corp by 2.9% in the third quarter. LS Investment Advisors LLC now owns 1,257 shares of the company’s stock worth $104,000 after buying an additional 36 shares during the last quarter. Elkfork Partners LLC purchased a new position in shares of Integra Lifesciences Holdings Corp during the fourth quarter valued at approximately $125,000. Acrospire Investment Management LLC increased its position in shares of Integra Lifesciences Holdings Corp by 66.7% in the third quarter. Acrospire Investment Management LLC now owns 1,500 shares of the company’s stock valued at $124,000 after buying an additional 600 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Integra Lifesciences Holdings Corp by 77.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,697 shares of the company’s stock valued at $100,000 after buying an additional 742 shares during the last quarter. Finally, Pacer Advisors Inc. purchased a new position in shares of Integra Lifesciences Holdings Corp during the third quarter valued at approximately $194,000. Hedge funds and other institutional investors own 44.37% of the company’s stock.

Integra Lifesciences Holdings Corp Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.